PacBio partners with Lucid Genomics for tertiary analysis of long-read sequencing data (pacb.com)

• Lucid Genomics joins PacBio Compatible partner program.
• Platform offers tertiary analysis for HiFi long-read data.
• Features: alignment, phasing, variant annotation, methylation.
• Goal: validated workflows from sequencing to clinical interpretation.

"PacBio (NASDAQ: PACB) announced that Lucid Genomics has joined the PacBio Compatible partner program. Lucid Genomics' platform provides tertiary analysis for HiFi long-read data, including alignment, phasing, variant annotation, and methylation analysis. The collaboration aims to deliver validated workflows from sequencing to clinical interpretation. Both companies plan joint customer engagements and co-marketing."